NCT00061620View on ClinicalTrials.gov

Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

September 6, 2001

Primary Completion Date

February 12, 2004

Study Completion Date

February 12, 2004

Conditions

Hematologic Malignancies

Interventions

DRUG

Tezacitabine (FMdC)

7.5 mg/m2 bolus infusion daily x 5

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Chiron Corporation

All Listed Sponsors

collaborator

Chiron Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00061620 - Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies | Biotech Hunter | Biotech Hunter